MX2022015739A - Inhibidores alostericos de egfr y metodos de uso de estos. - Google Patents
Inhibidores alostericos de egfr y metodos de uso de estos.Info
- Publication number
- MX2022015739A MX2022015739A MX2022015739A MX2022015739A MX2022015739A MX 2022015739 A MX2022015739 A MX 2022015739A MX 2022015739 A MX2022015739 A MX 2022015739A MX 2022015739 A MX2022015739 A MX 2022015739A MX 2022015739 A MX2022015739 A MX 2022015739A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- egfr inhibitors
- allosteric egfr
- compounds
- allosteric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063036622P | 2020-06-09 | 2020-06-09 | |
| US202063111429P | 2020-11-09 | 2020-11-09 | |
| PCT/US2021/036657 WO2021252661A1 (en) | 2020-06-09 | 2021-06-09 | Allosteric egfr inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015739A true MX2022015739A (es) | 2023-03-23 |
Family
ID=78846544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015739A MX2022015739A (es) | 2020-06-09 | 2021-06-09 | Inhibidores alostericos de egfr y metodos de uso de estos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230212171A1 (enExample) |
| EP (1) | EP4161516A4 (enExample) |
| JP (3) | JP7785701B2 (enExample) |
| KR (1) | KR20230033645A (enExample) |
| CN (1) | CN115811977A (enExample) |
| AU (1) | AU2021289729A1 (enExample) |
| BR (1) | BR112022025139A2 (enExample) |
| CA (1) | CA3181982A1 (enExample) |
| CO (1) | CO2022019316A2 (enExample) |
| EC (1) | ECSP22098041A (enExample) |
| IL (1) | IL298935A (enExample) |
| JO (1) | JOP20220332A1 (enExample) |
| MX (1) | MX2022015739A (enExample) |
| SA (1) | SA522441639B1 (enExample) |
| WO (1) | WO2021252661A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116490507A (zh) | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
| JP2025521540A (ja) * | 2022-06-21 | 2025-07-10 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 縮合二環式ｅｇｆｒ阻害剤およびその使用の方法 |
| GB202216962D0 (en) | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005021963A1 (de) * | 2005-05-12 | 2006-11-23 | Aicuris Gmbh & Co. Kg | Substituierte Dihydropyrazolotriazinone |
| JP5419706B2 (ja) * | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| WO2008130581A1 (en) * | 2007-04-20 | 2008-10-30 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
| US8394802B2 (en) * | 2008-09-19 | 2013-03-12 | Nerviano Medical Sciences S.R.L. | 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases |
| HK1252693A1 (zh) * | 2015-06-30 | 2019-05-31 | Dana Farber Cancer Institute, Inc. | Egfr抑制剂及其使用方法 |
| IL279800B2 (en) * | 2018-06-29 | 2024-02-01 | Hoffmann La Roche | Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use |
| CN112839937B (zh) * | 2018-08-16 | 2023-08-22 | 韩国化学研究院 | 异吲哚啉-1-酮衍生物、其制备方法及其用途 |
-
2021
- 2021-06-09 CN CN202180041075.2A patent/CN115811977A/zh active Pending
- 2021-06-09 CA CA3181982A patent/CA3181982A1/en active Pending
- 2021-06-09 JP JP2022576178A patent/JP7785701B2/ja active Active
- 2021-06-09 EP EP21821203.3A patent/EP4161516A4/en active Pending
- 2021-06-09 IL IL298935A patent/IL298935A/en unknown
- 2021-06-09 KR KR1020227043942A patent/KR20230033645A/ko active Pending
- 2021-06-09 BR BR112022025139A patent/BR112022025139A2/pt unknown
- 2021-06-09 AU AU2021289729A patent/AU2021289729A1/en active Pending
- 2021-06-09 MX MX2022015739A patent/MX2022015739A/es unknown
- 2021-06-09 US US18/000,722 patent/US20230212171A1/en active Pending
- 2021-06-09 WO PCT/US2021/036657 patent/WO2021252661A1/en not_active Ceased
-
2022
- 2022-12-07 SA SA522441639A patent/SA522441639B1/ar unknown
- 2022-12-08 JO JOJO/P/2022/0332A patent/JOP20220332A1/ar unknown
- 2022-12-28 EC ECSENADI202298041A patent/ECSP22098041A/es unknown
- 2022-12-30 CO CONC2022/0019316A patent/CO2022019316A2/es unknown
-
2025
- 2025-08-20 JP JP2025137145A patent/JP2025170326A/ja active Pending
- 2025-08-20 JP JP2025137144A patent/JP2025168374A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7785701B2 (ja) | 2025-12-15 |
| KR20230033645A (ko) | 2023-03-08 |
| ECSP22098041A (es) | 2023-06-30 |
| JP2025168374A (ja) | 2025-11-07 |
| AU2021289729A1 (en) | 2023-02-02 |
| BR112022025139A2 (pt) | 2023-02-14 |
| CN115811977A (zh) | 2023-03-17 |
| NZ795548A (en) | 2026-01-30 |
| US20230212171A1 (en) | 2023-07-06 |
| WO2021252661A1 (en) | 2021-12-16 |
| CO2022019316A2 (es) | 2023-01-16 |
| EP4161516A1 (en) | 2023-04-12 |
| SA522441639B1 (ar) | 2024-10-24 |
| JP2023529701A (ja) | 2023-07-11 |
| IL298935A (en) | 2023-02-01 |
| JOP20220332A1 (ar) | 2022-12-08 |
| CA3181982A1 (en) | 2021-12-16 |
| EP4161516A4 (en) | 2024-08-07 |
| JP2025170326A (ja) | 2025-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA522441639B1 (ar) | Egfr مثبطات تفارغية وطرق استخدامها | |
| MX2024004444A (es) | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| EP4360713A3 (en) | Quinazoline derivatives as antitumor agents | |
| MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
| MY183036A (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| MX2023004802A (es) | Compuestos espiro heterocíclicos y métodos de uso. | |
| EP4371562A3 (en) | 2-quinolone derived inhibitors of bcl6 | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| MX2022015410A (es) | Inhibidores de las cinasas receptoras del factor de crecimiento de fibroblastos. | |
| ZA202203520B (en) | [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| MX2023000577A (es) | Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa. | |
| MX2024006684A (es) | Inhibidores de hdac novedosos y uso terapéutico de estos. | |
| MX2024013266A (es) | Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina | |
| MX2024012937A (es) | Inhibidores del receptor del factor de crecimiento epidérmico en el tratamiento de cáncer | |
| MX2017014752A (es) | Nuevos etinos de amidoheteroaril aroil hidrazida. | |
| MX2025013034A (es) | Inhibidores de egfr para el tratamiento de enfermedades | |
| MX2021015898A (es) | Compuestos heterocíclicos bicíclicos como inhibidores de actividad de ofbcdin3d. | |
| MX2021007853A (es) | Compuestos de tienopiridinona. | |
| MX2025010608A (es) | Ureas biciclicas como inhibidores de cinasas | |
| MX2025007742A (es) | Inhibidores del receptor del factor de crecimiento epidermico (egfr) selectivos de mutantes | |
| ZA202107710B (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors |